1-1 By: McQueeney, et al. (Senate Sponsor - Hancock) H.B. No. 4535 1-2 (In the Senate - Received from the House May 15, 2025; 1-3 May 19, 2025, read first time and referred to Committee on Health & 1-4 Human Services; May 23, 2025, reported favorably by the following 1-5 vote: Yeas 7, Nays 1; May 23, 2025, sent to printer.)

COMMITTEE VOTE

1-7	Yea Nay Absent PNV	
1-8	Kolkhorst X	
1-9	Perry X Blanco X	
1-10 1-11	Blanco X Cook X	
1-11	Hall X	
1-12	Hancock X	
1-14	Hughes X	
1-15	Miles X	
1-16	Sparks X	
1-17	A BILL TO BE ENTITLED	
1-18	AN ACT	
1-19	relating to COVID-19 vaccine administration requirements.	
1-20	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:	
1-21	SECTION 1. Subchapter A, Chapter 161, Health and	Safety
1-22	Code, is amended by adding Section 161.0086 to read as follow	
1-23	Sec. 161.0086. COVID-19 VACCINATION ADMINIS	
1-24	REQUIREMENTS. (a) In this section:	
1-25		navirus
1-26	disease.	
1-27		ividual
1-28 1-29	licensed or otherwise authorized by this state to admi vaccines.	inister
1-29	(b) Before administering a COVID-19 vaccination	to an
1-31	individual, a health care provider must obtain the indiv	
1-32	written informed consent, or if the individual is a minor o	
1-33	the mental capacity to provide informed consent, the	
1-34	guardian, or conservator who may provide written informed	consent
1-35	on the individual's behalf. The informed consent required	
1-36	this section must include an acknowledgment that the ind	
1-37	providing informed consent received the information	sheet
1-38	described by Subsection (c).	
1-39 1-40	(c) The department shall develop a standardized info:	rmation
1-40 1-41	sheet that includes information on: (1) the benefits and risks associated with CO	19 – 19
1-42	vaccination, including potential side effects;	<u>JVID IJ</u>
1-43	(2) the expedited manner in which the COVID-19	vaccine
1-44	was developed;	
1-45	(3) whether long-term scientific studies hav	re been
1-46	performed on the COVID-19 vaccine;	
1-47	(4) whether manufacturers of the COVID-19 vacc	
1-48	subject to civil liability for any injuries caused by the va	accine;
1-49	and (5) the following and	
1-50	(5) the federal Vaccine Adverse Event Rep	
1 - 51 1 - 52	System, including clear instructions for reportin vaccine-related injury or reaction.	g any
1-52 1 - 53	(d) The appropriate licensing authority may	impose
1-54	disciplinary action on a health care provider who adminis	
1-55	COVID-19 vaccination in violation of this section in th	
1-56	manner and using the same procedures as the authority uses to	
1-57	disciplinary action on a provider who violates the auth	ority's
1-58	licensing or other regulatory laws or rules.	
1-59	SECTION 2. This Act takes effect September 1, 2025.	

1-60

1-6

* * * * *